原始细胞CD33的表达水平对吉妥珠单抗奥唑米星治疗急性髓性白血病患者的疗效有积极影响。 - Suppr

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

作者信息

Olombel Guillaume, Guerin Estelle, Guy Julien, Perrot Jean-Yves, Dumezy Florent, de Labarthe Adrienne, Bastie Jean-Noël, Legrand Ollivier, Raffoux Emmanuel, Plesa Adriana, Wagner-Ballon Orianne, Cornet Edouard, Salaun Véronique, Preudhomme Claude, Thomas Xavier, Pautas Cécile, Chantepie Sylvain, Turlure Pascal, Castaigne Sylvie, Dombret Hervé, Feuillard Jean

机构信息

Laboratoire d'Hématologie et Unité Mixte de Recherche 7276 Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire (CHU) de Limoges, Faculté de Médecine, Université de Limoges et Centre National de la Recherche Scientifique, Limoges, France;

Service d'Hématologie Biologique, CHU, Dijon, France;

出版信息

Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29.

DOI:10.1182/blood-2016-01-689976

PMID:26929274

Abstract

摘要

相似文献

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29.

Gemtuzumab ozogamicin for acute myeloid leukemia.

Blood. 2017 Nov 30;130(22):2373-2376. doi: 10.1182/blood-2017-09-797712. Epub 2017 Oct 11.

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.

Blood. 2018 Jan 25;131(4):468-471. doi: 10.1182/blood-2017-08-802157. Epub 2017 Dec 11.

Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

Future Oncol. 2018 Dec;14(30):3199-3213. doi: 10.2217/fon-2018-0325. Epub 2018 Jul 24.

[Anti-CD33 monoclonal antibody drug conjugate--Gemtuzumab ozogamicin (GO)].

Nihon Rinsho. 2015 Feb;73 Suppl 2:215-8.

Gemtuzumab Ozogamicin Makes a Comeback.

Cancer Discov. 2017 Nov;7(11):1208. doi: 10.1158/2159-8290.CD-NB2017-132. Epub 2017 Sep 20.

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.

Leukemia. 2017 May;31(5):1059-1068. doi: 10.1038/leu.2016.309. Epub 2016 Oct 31.

Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study.

Leukemia. 2009 Feb;23(2):402-4. doi: 10.1038/leu.2008.185. Epub 2008 Jul 10.

Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.

Front Biosci (Landmark Ed). 2013 Jun 1;18(4):1311-34. doi: 10.2741/4181.

Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.

Expert Opin Biol Ther. 2008 Apr;8(4):527-40. doi: 10.1517/14712598.8.4.527.

引用本文的文献

Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals.

J Hematol Oncol. 2025 Apr 30;18(1):51. doi: 10.1186/s13045-025-01704-3.

Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities.

J Pers Med. 2025 Jan 26;15(2):49. doi: 10.3390/jpm15020049.

Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy.

Expert Rev Clin Immunol. 2024 Jul;20(7):745-763. doi: 10.1080/1744666X.2024.2349738. Epub 2024 May 14.

Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review.

Biomedicines. 2024 Jan 17;12(1):208. doi: 10.3390/biomedicines12010208.

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.

Signal Transduct Target Ther. 2023 Aug 18;8(1):306. doi: 10.1038/s41392-023-01521-5.

Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin.

Onco Targets Ther. 2023 Apr 29;16:297-308. doi: 10.2147/OTT.S263829. eCollection 2023.

The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience.

Medicina (Kaunas). 2023 Mar 2;59(3):498. doi: 10.3390/medicina59030498.

GSK3 inhibitor enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance.

EJHaem. 2022 Dec 12;4(1):153-164. doi: 10.1002/jha2.600. eCollection 2023 Feb.

Role of Biomarkers in the Management of Acute Myeloid Leukemia.

Int J Mol Sci. 2022 Nov 22;23(23):14543. doi: 10.3390/ijms232314543.

Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia.

Front Oncol. 2022 May 19;12:826768. doi: 10.3389/fonc.2022.826768. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献